ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antihemophilic Factor Drug Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-31A6832
Home | Market Reports | Health| Pharmacy
Global Antihemophilic Factor Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Antihemophilic Factor Drug Market Research Report 2025

Code: QYRE-Auto-31A6832
Report
August 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Takeda
Novo Nordisk
Pfizer Inc
Grifols S A
CSL Behring
Sanofi
Cigna
Octapharma AG
GC Pharma
Hualan Biological Engineering
Shanghai RAAS Blood Products

Antihemophilic Factor Drug Market Size

The global market for Antihemophilic Factor Drug was valued at US$ 589 million in the year 2024 and is projected to reach a revised size of US$ 886 million by 2031, growing at a CAGR of 6.1% during the forecast period.

Antihemophilic Factor Drug Market

Antihemophilic Factor Drug Market

Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor Drug.
The Antihemophilic Factor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antihemophilic Factor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihemophilic Factor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Antihemophilic Factor Drug Market Report

Report Metric Details
Report Name Antihemophilic Factor Drug Market
Accounted market size in year US$ 589 million
Forecasted market size in 2031 US$ 886 million
CAGR 6.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • Other potencies
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bayer, Takeda, Novo Nordisk, Pfizer, Grifols, CSL Behring, Sanofi, Cigna, Octapharma, GC Pharma, Hualan Biological Engineering, Shanghai RAAS blood products
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Antihemophilic Factor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Antihemophilic Factor Drug Market growing?

Ans: The Antihemophilic Factor Drug Market witnessing a CAGR of 6.1% during the forecast period 2025-2031.

What is the Antihemophilic Factor Drug Market size in 2031?

Ans: The Antihemophilic Factor Drug Market size in 2031 will be US$ 886 million.

Who are the main players in the Antihemophilic Factor Drug Market report?

Ans: The main players in the Antihemophilic Factor Drug Market are Bayer, Takeda, Novo Nordisk, Pfizer, Grifols, CSL Behring, Sanofi, Cigna, Octapharma, GC Pharma, Hualan Biological Engineering, Shanghai RAAS blood products

What are the Application segmentation covered in the Antihemophilic Factor Drug Market report?

Ans: The Applications covered in the Antihemophilic Factor Drug Market report are Adult, Pediatric

What are the Type segmentation covered in the Antihemophilic Factor Drug Market report?

Ans: The Types covered in the Antihemophilic Factor Drug Market report are 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU, 4000 IU, Other potencies

Recommended Reports

Hemophilia Treatments

Coagulation & Clotting

Pharmaceutical Testing

1 Antihemophilic Factor Drug Market Overview
1.1 Product Definition
1.2 Antihemophilic Factor Drug by Type
1.2.1 Global Antihemophilic Factor Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 250 IU
1.2.3 500 IU
1.2.4 1000 IU
1.2.5 1500 IU
1.2.6 2000 IU
1.2.7 3000 IU
1.2.8 4000 IU
1.2.9 Other potencies
1.3 Antihemophilic Factor Drug by Application
1.3.1 Global Antihemophilic Factor Drug Market Value by Application (2024 VS 2031)
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts
1.4.1 Global Antihemophilic Factor Drug Revenue 2020-2031
1.4.2 Global Antihemophilic Factor Drug Sales 2020-2031
1.4.3 Global Antihemophilic Factor Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Antihemophilic Factor Drug Market Competition by Manufacturers
2.1 Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Antihemophilic Factor Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Antihemophilic Factor Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antihemophilic Factor Drug, Product Type & Application
2.7 Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
2.8 Global Antihemophilic Factor Drug Market Competitive Situation and Trends
2.8.1 Global Antihemophilic Factor Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Antihemophilic Factor Drug Players Market Share by Revenue
2.8.3 Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antihemophilic Factor Drug Market Scenario by Region
3.1 Global Antihemophilic Factor Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Antihemophilic Factor Drug Sales by Region: 2020-2031
3.2.1 Global Antihemophilic Factor Drug Sales by Region: 2020-2025
3.2.2 Global Antihemophilic Factor Drug Sales by Region: 2026-2031
3.3 Global Antihemophilic Factor Drug Revenue by Region: 2020-2031
3.3.1 Global Antihemophilic Factor Drug Revenue by Region: 2020-2025
3.3.2 Global Antihemophilic Factor Drug Revenue by Region: 2026-2031
3.4 North America Antihemophilic Factor Drug Market Facts & Figures by Country
3.4.1 North America Antihemophilic Factor Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Antihemophilic Factor Drug Sales by Country (2020-2031)
3.4.3 North America Antihemophilic Factor Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antihemophilic Factor Drug Market Facts & Figures by Country
3.5.1 Europe Antihemophilic Factor Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Antihemophilic Factor Drug Sales by Country (2020-2031)
3.5.3 Europe Antihemophilic Factor Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antihemophilic Factor Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Antihemophilic Factor Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Antihemophilic Factor Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Antihemophilic Factor Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antihemophilic Factor Drug Market Facts & Figures by Country
3.7.1 Latin America Antihemophilic Factor Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Antihemophilic Factor Drug Sales by Country (2020-2031)
3.7.3 Latin America Antihemophilic Factor Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antihemophilic Factor Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Antihemophilic Factor Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Antihemophilic Factor Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antihemophilic Factor Drug Sales by Type (2020-2031)
4.1.1 Global Antihemophilic Factor Drug Sales by Type (2020-2025)
4.1.2 Global Antihemophilic Factor Drug Sales by Type (2026-2031)
4.1.3 Global Antihemophilic Factor Drug Sales Market Share by Type (2020-2031)
4.2 Global Antihemophilic Factor Drug Revenue by Type (2020-2031)
4.2.1 Global Antihemophilic Factor Drug Revenue by Type (2020-2025)
4.2.2 Global Antihemophilic Factor Drug Revenue by Type (2026-2031)
4.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Type (2020-2031)
4.3 Global Antihemophilic Factor Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Antihemophilic Factor Drug Sales by Application (2020-2031)
5.1.1 Global Antihemophilic Factor Drug Sales by Application (2020-2025)
5.1.2 Global Antihemophilic Factor Drug Sales by Application (2026-2031)
5.1.3 Global Antihemophilic Factor Drug Sales Market Share by Application (2020-2031)
5.2 Global Antihemophilic Factor Drug Revenue by Application (2020-2031)
5.2.1 Global Antihemophilic Factor Drug Revenue by Application (2020-2025)
5.2.2 Global Antihemophilic Factor Drug Revenue by Application (2026-2031)
5.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Application (2020-2031)
5.3 Global Antihemophilic Factor Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bayer Antihemophilic Factor Drug Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Takeda
6.2.1 Takeda Company Information
6.2.2 Takeda Description and Business Overview
6.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Takeda Antihemophilic Factor Drug Product Portfolio
6.2.5 Takeda Recent Developments/Updates
6.3 Novo Nordisk
6.3.1 Novo Nordisk Company Information
6.3.2 Novo Nordisk Description and Business Overview
6.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio
6.3.5 Novo Nordisk Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Antihemophilic Factor Drug Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Company Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Grifols Antihemophilic Factor Drug Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 CSL Behring
6.6.1 CSL Behring Company Information
6.6.2 CSL Behring Description and Business Overview
6.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CSL Behring Antihemophilic Factor Drug Product Portfolio
6.6.5 CSL Behring Recent Developments/Updates
6.7 Sanofi
6.7.1 Sanofi Company Information
6.7.2 Sanofi Description and Business Overview
6.7.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Sanofi Antihemophilic Factor Drug Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Cigna
6.8.1 Cigna Company Information
6.8.2 Cigna Description and Business Overview
6.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Cigna Antihemophilic Factor Drug Product Portfolio
6.8.5 Cigna Recent Developments/Updates
6.9 Octapharma
6.9.1 Octapharma Company Information
6.9.2 Octapharma Description and Business Overview
6.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Octapharma Antihemophilic Factor Drug Product Portfolio
6.9.5 Octapharma Recent Developments/Updates
6.10 GC Pharma
6.10.1 GC Pharma Company Information
6.10.2 GC Pharma Description and Business Overview
6.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 GC Pharma Antihemophilic Factor Drug Product Portfolio
6.10.5 GC Pharma Recent Developments/Updates
6.11 Hualan Biological Engineering
6.11.1 Hualan Biological Engineering Company Information
6.11.2 Hualan Biological Engineering Description and Business Overview
6.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio
6.11.5 Hualan Biological Engineering Recent Developments/Updates
6.12 Shanghai RAAS blood products
6.12.1 Shanghai RAAS blood products Company Information
6.12.2 Shanghai RAAS blood products Description and Business Overview
6.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio
6.12.5 Shanghai RAAS blood products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antihemophilic Factor Drug Industry Chain Analysis
7.2 Antihemophilic Factor Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antihemophilic Factor Drug Production Mode & Process Analysis
7.4 Antihemophilic Factor Drug Sales and Marketing
7.4.1 Antihemophilic Factor Drug Sales Channels
7.4.2 Antihemophilic Factor Drug Distributors
7.5 Antihemophilic Factor Drug Customer Analysis
8 Antihemophilic Factor Drug Market Dynamics
8.1 Antihemophilic Factor Drug Industry Trends
8.2 Antihemophilic Factor Drug Market Drivers
8.3 Antihemophilic Factor Drug Market Challenges
8.4 Antihemophilic Factor Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bayer
Takeda
Novo Nordisk
Pfizer Inc
Grifols S A
CSL Behring
Sanofi
Cigna
Octapharma AG
GC Pharma
Hualan Biological Engineering
Shanghai RAAS Blood Products
List of Tables
 Table 1. Global Antihemophilic Factor Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Antihemophilic Factor Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Antihemophilic Factor Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Antihemophilic Factor Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Antihemophilic Factor Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Antihemophilic Factor Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Antihemophilic Factor Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Antihemophilic Factor Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Antihemophilic Factor Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Antihemophilic Factor Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Antihemophilic Factor Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Antihemophilic Factor Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Antihemophilic Factor Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Antihemophilic Factor Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Antihemophilic Factor Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Antihemophilic Factor Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Antihemophilic Factor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Antihemophilic Factor Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Antihemophilic Factor Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Antihemophilic Factor Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Antihemophilic Factor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Antihemophilic Factor Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Antihemophilic Factor Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Antihemophilic Factor Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Antihemophilic Factor Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Antihemophilic Factor Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Antihemophilic Factor Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Antihemophilic Factor Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Antihemophilic Factor Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antihemophilic Factor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Antihemophilic Factor Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Antihemophilic Factor Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Antihemophilic Factor Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Antihemophilic Factor Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Antihemophilic Factor Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Antihemophilic Factor Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Antihemophilic Factor Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Antihemophilic Factor Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Antihemophilic Factor Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Antihemophilic Factor Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Antihemophilic Factor Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Antihemophilic Factor Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Antihemophilic Factor Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Antihemophilic Factor Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Antihemophilic Factor Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Antihemophilic Factor Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Antihemophilic Factor Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Antihemophilic Factor Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Antihemophilic Factor Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Antihemophilic Factor Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Antihemophilic Factor Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Antihemophilic Factor Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2026-2031)
 Table 70. Bayer Company Information
 Table 71. Bayer Description and Business Overview
 Table 72. Bayer Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Bayer Antihemophilic Factor Drug Product
 Table 74. Bayer Recent Developments/Updates
 Table 75. Takeda Company Information
 Table 76. Takeda Description and Business Overview
 Table 77. Takeda Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Takeda Antihemophilic Factor Drug Product
 Table 79. Takeda Recent Developments/Updates
 Table 80. Novo Nordisk Company Information
 Table 81. Novo Nordisk Description and Business Overview
 Table 82. Novo Nordisk Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Novo Nordisk Antihemophilic Factor Drug Product
 Table 84. Novo Nordisk Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Pfizer Antihemophilic Factor Drug Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Grifols Company Information
 Table 91. Grifols Description and Business Overview
 Table 92. Grifols Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Grifols Antihemophilic Factor Drug Product
 Table 94. Grifols Recent Developments/Updates
 Table 95. CSL Behring Company Information
 Table 96. CSL Behring Description and Business Overview
 Table 97. CSL Behring Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. CSL Behring Antihemophilic Factor Drug Product
 Table 99. CSL Behring Recent Developments/Updates
 Table 100. Sanofi Company Information
 Table 101. Sanofi Description and Business Overview
 Table 102. Sanofi Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Sanofi Antihemophilic Factor Drug Product
 Table 104. Sanofi Recent Developments/Updates
 Table 105. Cigna Company Information
 Table 106. Cigna Description and Business Overview
 Table 107. Cigna Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Cigna Antihemophilic Factor Drug Product
 Table 109. Cigna Recent Developments/Updates
 Table 110. Octapharma Company Information
 Table 111. Octapharma Description and Business Overview
 Table 112. Octapharma Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Octapharma Antihemophilic Factor Drug Product
 Table 114. Octapharma Recent Developments/Updates
 Table 115. GC Pharma Company Information
 Table 116. GC Pharma Description and Business Overview
 Table 117. GC Pharma Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. GC Pharma Antihemophilic Factor Drug Product
 Table 119. GC Pharma Recent Developments/Updates
 Table 120. Hualan Biological Engineering Company Information
 Table 121. Hualan Biological Engineering Description and Business Overview
 Table 122. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Hualan Biological Engineering Antihemophilic Factor Drug Product
 Table 124. Hualan Biological Engineering Recent Developments/Updates
 Table 125. Shanghai RAAS blood products Company Information
 Table 126. Shanghai RAAS blood products Description and Business Overview
 Table 127. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Shanghai RAAS blood products Antihemophilic Factor Drug Product
 Table 129. Shanghai RAAS blood products Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Antihemophilic Factor Drug Distributors List
 Table 133. Antihemophilic Factor Drug Customers List
 Table 134. Antihemophilic Factor Drug Market Trends
 Table 135. Antihemophilic Factor Drug Market Drivers
 Table 136. Antihemophilic Factor Drug Market Challenges
 Table 137. Antihemophilic Factor Drug Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Antihemophilic Factor Drug
 Figure 2. Global Antihemophilic Factor Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antihemophilic Factor Drug Market Share by Type: 2024 & 2031
 Figure 4. 250 IU Product Picture
 Figure 5. 500 IU Product Picture
 Figure 6. 1000 IU Product Picture
 Figure 7. 1500 IU Product Picture
 Figure 8. 2000 IU Product Picture
 Figure 9. 3000 IU Product Picture
 Figure 10. 4000 IU Product Picture
 Figure 11. Other potencies Product Picture
 Figure 12. Global Antihemophilic Factor Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 13. Global Antihemophilic Factor Drug Market Share by Application: 2024 & 2031
 Figure 14. Adult
 Figure 15. Pediatric
 Figure 16. Global Antihemophilic Factor Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Antihemophilic Factor Drug Market Size (2020-2031) & (US$ Million)
 Figure 18. Global Antihemophilic Factor Drug Sales (2020-2031) & (K Units)
 Figure 19. Global Antihemophilic Factor Drug Average Price (USD/Unit) & (2020-2031)
 Figure 20. Antihemophilic Factor Drug Report Years Considered
 Figure 21. Antihemophilic Factor Drug Sales Share by Manufacturers in 2024
 Figure 22. Global Antihemophilic Factor Drug Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest Antihemophilic Factor Drug Players: Market Share by Revenue in Antihemophilic Factor Drug in 2024
 Figure 24. Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global Antihemophilic Factor Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America Antihemophilic Factor Drug Sales Market Share by Country (2020-2031)
 Figure 27. North America Antihemophilic Factor Drug Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe Antihemophilic Factor Drug Sales Market Share by Country (2020-2031)
 Figure 31. Europe Antihemophilic Factor Drug Revenue Market Share by Country (2020-2031)
 Figure 32. Germany Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific Antihemophilic Factor Drug Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific Antihemophilic Factor Drug Revenue Market Share by Region (2020-2031)
 Figure 39. China Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Antihemophilic Factor Drug Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Antihemophilic Factor Drug Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Antihemophilic Factor Drug Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Antihemophilic Factor Drug Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE Antihemophilic Factor Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Antihemophilic Factor Drug by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Antihemophilic Factor Drug by Type (2020-2031)
 Figure 61. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Antihemophilic Factor Drug by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Antihemophilic Factor Drug by Application (2020-2031)
 Figure 64. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2020-2031)
 Figure 65. Antihemophilic Factor Drug Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Recombinant Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor Recombinant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor von Willebrand Factor Complex Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cryoprecipitated Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hemophilia Medication Market Research Report 2024
Global Recombinant Antihemophilic Globulin Market Research Report 2024
Global Recombinant Coagulation Factor Concentrate Market Research Report 2024
Hemophilia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Coagulation Factor VIII Market Research Report 2020
Global Coagulation Factor Concentrate Market Research Report 2025
Rare Hemophilia Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hemostatic Powders and Hemostatic Agents Market Research Report 2025
Global Hemophilia A Drug Market Research Report 2024
Haemophilia Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biosimilars of Factor X agonists Market Research Report 2024
Global Haemophilia Treatment Market Insights Forecast to 2030

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions